Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 1:47 AM
Ignite Modification Date: 2025-12-25 @ 1:47 AM
NCT ID: NCT04724694
Eligibility Criteria: Inclusion Criteria: * Veterans age \>=18 and \<=79 years * Conversant in English * A diagnosis of musculoskeletal pain of \>three months * PEG score of \>= 4 on pain intensity item and both interference items at screening * BPI interference and pain intensity score of at least 4.0 at baseline * If currently prescribed pain medication (other than topicals or NSAIDS), a stable dose in the last two months * If currently prescribed psychiatric medicine, a stable dose in the last two months * Established history of VA primary care utilization (i.e., at least one primary care visit in the past year) Exclusion Criteria: * Current or prior (past 12 months) engagement in psychotherapy or behavioral intervention provided by behavioral medicine services or specialty mental health for chronic pain. * Medication management through psychiatric services or an on-going course of mental health services for issues other than chronic pain are not excluded. * Endorsement of imminent suicide risk * Current significant substance use problems (i.e., alcohol, opioids, benzodiazepines, or other drugs) * Unstable psychiatric status (e.g., active psychosis, current mania) * Diagnosed with major or minor neurocognitive disorder * Unwilling to have treatment sessions audio recorded * Pending disability claim * Recent or planned surgical/interventional procedure for pain
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 79 Years
Study: NCT04724694
Study Brief:
Protocol Section: NCT04724694